ArticleCancer immunology, immunotherapy : CII2013
The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer.
Article in Cancer immunology, immunotherapy : CII, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 35 citations in OpenAlex.
- Phase 2 trial of pTVG-HP ± pTVG-AR DNA vaccines and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC).Journal for immunotherapy of cancer · 2026Trial
- Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer.Journal for immunotherapy of cancer · 2026Trial
- Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Trial
- Activation of tumor-specific CD8+ T cells prior to radiopharmaceutical therapy improves antitumor response.Journal for immunotherapy of cancer · 2026Article
- Plasmid DNA vaccines encapsulated in lipid nanoparticles elicit STING-dependent type 1 interferon release.Molecular therapy. Advances · 2026Article
- PD-1 blockade employed at the time CD8+ T cells are activated enhances their antitumor efficacy.Journal for immunotherapy of cancer · 2025Article
- Tracing the Evolution of Sex Hormones and Receptor-Mediated Immune Microenvironmental Differences in Prostate and Bladder Cancers: From Embryonic Development to Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Sequence of androgen receptor-targeted vaccination with androgen deprivation therapy affects anti-prostate tumor efficacy.Journal for immunotherapy of cancer · 2024Article
- Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy.Journal for immunotherapy of cancer · 2024Article
- Preclinical support for tumor protein D52 as a cancer vaccine antigen.Human vaccines & immunotherapeutics · 2023Review
- Advances in bio-immunotherapy for castration-resistant prostate cancer.Journal of cancer research and clinical oncology · 2023Review
- Vaccines as treatments for prostate cancer.Nature reviews. Urology · 2023Review
- Current status and progress of the development of prostate cancer vaccines.Journal of Cancer · 2023Review
- Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expression.Oncoimmunology · 2022Article
- PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy.Oncoimmunology · 2021Article
- Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer.Cancers · 2021Review
- Influence of Androgens on Immunity to Self and Foreign: Effects on Immunity and Cancer.Frontiers in immunology · 2020Review
- Escape hematopoiesis by HLA-B5401-lacking hematopoietic stem progenitor cells in men with acquired aplastic anemia.Haematologica · 2019Article
- Androgen deprivation and immunotherapy for the treatment of prostate cancer.Endocrine-related cancer · 2017Review
- Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells.Cancer immunology research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The androgen receptor (AR) plays an essential role in the development and progression of prostate cancer. However, while it has long been the primary molecular target of metastatic prostate cancer therapies, it has not been explored as an immunotherapeutic target. In particular, the AR ligand-binding domain (LBD) is a potentially attractive target, as it has an identical sequence among humans as well as among multiple species, providing a logical candidate for preclinical evaluation. In this report, we evaluated the immune and anti-tumor efficacy of a DNA vaccine targeting the AR LBD (pTVG-AR) in relevant rodent preclinical models. We found immunization of HHDII-DR1 mice, which express human HLA-A2 and HLA-DR1, with pTVG-AR augmented AR LBD HLA-A2-restricted peptide-specific, cytotoxic immune responses in vivo that could lyse human prostate cancer cells. Using an HLA-A2-expressing autochthonous model of prostate cancer, immunization with pTVG-AR augmented HLA-A2-restricted immune responses that could lyse syngeneic prostate tumor cells and led to a decrease in tumor burden and an increase in overall survival of tumor-bearing animals. Finally, immunization decreased prostate tumor growth in Copenhagen rats that was associated with a Th1-type immune response. These data show that the AR is as a prostate cancer immunological target antigen and that a DNA vaccine targeting the AR LBD is an attractive candidate for clinical evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.